CHOOLIP & SCIENCES Inc. (KOSDAQ:291650)
2,595.00
+15.00 (0.58%)
At close: Oct 16, 2026
CHOOLIP & SCIENCES Revenue
In the year 2024, CHOOLIP & SCIENCES had annual revenue of 1.08B KRW with 345.26% growth. CHOOLIP & SCIENCES had revenue of 920.07M in the quarter ending December 31, 2024, with 5,471.58% growth. That makes CHOOLIP & SCIENCES the 43,911th largest company in the world by revenue and 2,585th in South Korea.
Revenue
1.08B
Revenue Growth
+281.58%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
79.20B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.08B | 839.63M | 345.26% |
| Dec 31, 2023 | 243.19M | -115.07M | -32.12% |
| Dec 31, 2022 | 358.25M | 88.98M | 33.04% |
| Dec 31, 2021 | 269.28M | 40.77M | 17.84% |
| Dec 31, 2020 | 228.51M | -179.09M | -43.94% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CTCBIO | 131.54B |
| Cell Biotech | 60.40B |
| Choong Ang Vaccine Laboratory | 39.19B |
| Prestige Biologics | 26.67B |
| Naturalendo Tech | 22.79B |
| BIO-FD&C | 19.53B |
| CORESTEMCHEMON | 18.29B |
| EyeGene | 4.48B |